Elena A. Denisova

Elena A. Denisova

Auto-generated profile, based on publicly available information

Elena A. Denisova

Moscow State Budgetary Healthcare Institution «Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2024 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
MLM. A. Lyadova
M. A. Lyadova
EDE. A. Denisova
E. A. Denisova
DFDenis Fedorinov
Denis Fedorinov
YEYu. S. Esakov
Yu. S. Esakov
AOAleksandra Sergeevna Orlova
Aleksandra Sergeevna Orlova
VGV. N. Galkin
V. N. Galkin
Introduction. Non-small cell lung cancer (NSCLC) is a form of lung cancer with high incidence and low overall survival. Immunotherapy is a promising treatment method for which the selection of optimal treatment regimens for each individual patient is important.Aim. To evaluate the effectiveness and safety of immune checkpoint inhibitors (ICIs) in patients with advanced NSCLC.Materials and methods. The study included 247 patients (190 men and 57 women) aged 37 to 87 years who received ICIs as monotherapy with nivolumab (n = 58; 23.4%), pembrolizumab (n = 78; 31.6%) and atezolizumab (n = 13; 5.3%), and in the form of combination chemoimmune therapy (n = 98; 39.7%). The objective response of the tumor to treatment was recorded in the presence of partial or complete regression of the tumor. The tumor response to treatment was determined in accordance with the iRECIST criteria.Results. Objective response was achieved in 20.6% of patients, of which 13.7% were on the first line setting, and 7% of patients were on the 2nd or more line setting. Disease control was recorded in 83.3% of patients. Patients receiving combination chemoimmune therapy had a better response to treatment than those receiving monotherapy (χ2 = 9.309; p = 0.020). Grade 3–4 immuno-related adverse events were observed only in 5 (2.02%) patients.Conclusions. NSCLC immunotherapy allows to achieve high rates of objective response and disease control (20.6 and 83.3%, respectively), with a small number of grade 3–4 immuno-related adverse events (2.02% according to our data), which indicates an acceptable safety profile.

29 July 2026 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
JMJulia S. Mansurova
Julia S. Mansurova
МСМансурова Юлия Сергеевна
Мансурова Юлия Сергеевна
MLMarina A. Lyadova
Marina A. Lyadova
ЛАЛядова Марина Александровна
Лядова Марина Александровна
EDElena A. Denisova
Elena A. Denisova
ЛКЛядов Владимир Константинович
Лядов Владимир Константинович
Background. Small cell lung cancer (SCLC) accounts for about 15% of all lung cancer cases. It is characterized by aggressive progression, high proliferative capacity, and early hematogenous and lymphogenous dissemination. Although there is a significant baseline sensitivity to first-line chemotherapy, the majority of patients experience disease progression within 6 to 12 months following treatment initiation, with a median overall survival of approximately 12 months. Aim. To evaluate the efficacy and safety of first-line therapy utilizing atezolizumab combined with carboplatin or cisplatin and etoposide in patients diagnosed with SCLC in a real-world context. Materials and methods. This retrospective and prospective observational study included 157 patients (119 males and 38 females) aged 32 to 84 years. Compromised performance status (ECOG 2–3) at baseline was observed in 54 patients (34.4%). Results. The median progression-free survival in patients with SCLC undergoing first-line therapy was 6.18 months (95% confidence interval [CI] 5.69-6.90), while the median overall survival was 10.55 months (95% CI 8.12-13.02). An objective response was recorded in 82 patients (52.3%). Grade 3–4 immune-related adverse events were documented in only 5.1% of the patient population. Conclusion. The combination of atezolizumab with platinum-based chemotherapy and etoposide as a first-line treatment for SCLC demonstrates high efficacy and an acceptable safety profile in real-world clinical settings.

27 June 2025 in P.A. Herzen Journal of Oncology
Verified
Journal Article
Closed access
EDE.A. Denisova
E.A. Denisova
MLM.A. Lyadova
M.A. Lyadova
EKE.S. Kuzmina
E.S. Kuzmina
TAT.G. Antonova
T.G. Antonova
Non-small cell lung cancer (NSCLC) is a form of lung cancer characterized by high incidence and low overall survival rates. The advent of immune checkpoint inhibitor therapy has transformed the treatment approach and clinical course of many cancers, including NSCLC. Monotherapy with immunotherapy or its combination with chemotherapy has become the established first-line treatment for advanced NSCLC without sensitizing mutations. Objective. To evaluate the efficacy of chemoimmunotargeted therapy (atezolizumab+paclitaxel+carboplatin+bevacizumab) in patients with advanced NSCLC in real-world clinical practice. Material and methods. The study included 25 patients aged 42 to 80 years who received chemoimmunotargeted therapy. Of these, 11 (44%) were treated in the first line, and 14 (56%) in the second or subsequent lines. An EGFR mutation was identified in 10 (40%) patients and an ALK translocation in 1 (4%). Results. The median follow-up was 11.7 (range 1.1—47.1) months. An objective response (complete+partial response) was achieved in 10 (40%) patients, while disease control (objective response+stable disease) was recorded in 23 (92%) patients. Median progression-free survival (PFS) and overall survival (OS) for first-line treatment were not reached. For second-line treatment, median PFS and OS were 8 months and 12.9 months, respectively. The safety profile was manageable, with 5 (20%) cases of immune-mediated adverse events reported. Conclusion. The atezolizumab+paclitaxel+carboplatin+bevacizumab regimen represents a potential first-line treatment option for advanced NSCLC, including cases with EGFR mutations after progression on tyrosine kinase inhibitor therapy, regardless of PD-L1 status.

21 February 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
MLMarina A. Lyadova
Marina A. Lyadova
TNTatiana A. Nersesova
Tatiana A. Nersesova
AZAnastasia A. Zhuravleva
Anastasia A. Zhuravleva
DFDenis Fedorinov
Denis Fedorinov
ADAnna A. Dudnik
Anna A. Dudnik
OBOlesya A. Bikmurzina
Olesya A. Bikmurzina
Background. Alopecia is one of the main side effects of anticancer chemotherapy and has a significant impact on patients’ appearance, quality of life, social adaptation and mental health of cancer patients. Estimated number of new cancer diagnosis increases annually alongside with the proportion of patients receiving chemotherapy. That means an annual increase in the global burden of chemo-induced alopecia and associated negative consequences. The development of various methods for the prevention of alopecia in cancer patients has continued for decades. However, convincing data have been obtained only for the scalp hypothermia method. In this point, the Paxman company’s cooling systems (UK) – the Orbis and Orbis II devices – have been most widely studied. Despite the fact that Orbis devices were approved in Russia more than 10 years ago, since then just a small amount of real clinical practice has been accumulated and questions regarding the effectiveness of scalp hypothermia in patients with variable cancers still remain open. Aim. Analysis of local clinical practice with scalp hypothermia via the Orbis II device for the prevention of alopecia in patients receiving various chemotherapy regimens. Materials and methods. An open, prospective, single-center study included patients with various cancer types who were indicated for chemotherapy. Orbis II device was used for prophylactic hypothermia. The severity of alopecia was assessed according to the CTCAE version 5.0 at baseline and during anticancer therapy. Results. From June 2022 to May 2023, scalp cooling procedures were performed in 51 patients, of them 78% of all procedures were performed in female cancers: breast tumors – 109 (52.2%) procedures, ovarian cancer– 33 (15.8%), and cervix cancer – 22 (10.5%). The effectiveness of scalp hypothermia in preventing of severe alopecia was 73%. Conclusion. Scalp cooling can be considered as an effective method for the prevention of chemotherapy induced alopecia. Further studies are needed to assess larger patient populations to identify favorable and negative factors that affect potency of the hypothermia.

1 January 2026 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
JMJu. S. Mansurova
Ju. S. Mansurova
MLM. A. Lyadova
M. A. Lyadova
EDE. A. Denisova
E. A. Denisova
ЕКЕ. С. Кузьмина
Е. С. Кузьмина
Vladimir K. LyadovVladimir K. Lyadov
Vladimir K. Lyadov
Introduction . Small cell lung cancer (SCLC) accounts for approximately 15–20% of all lung cancer cases. The addition of PD-L1 inhibitors to platinum-etoposide chemotherapy has become the standard of care first-line treatment of SCLC. IMpower133 study revealed that immune-related adverse events (irAEs) were observed in 33.3% of patients, with only 4% of cases discontinuing treatment owing to irAEs, which indicates an acceptable safety profile. Aim . To analyse the toxicity profile of atezolizumab in combination with chemotherapy in the first-line treatment of patients with small cell lung cancer in real-world clinical practice. Materials and methods . This prospective/retrospective, non-randomized, single-site study included 157 patients aged 32 to 84 years with advanced SCLC, who received atezolizumab + carboplatin/cisplatin + etoposide as first-line chemoimmunotherapy over the 2019 to 2025 period at the S. S. Yudin City Clinical Hospital. 101 (65.6%) patients showed a satisfactory ECOG performance status (ECOG 0-1), whereas 54 (34.4%) patients showed ECOG PS of 2-3. Results . Grade 3-4 irAEs were diagnosed in 8 patients (5.1%). 14 patients (8.92%) were assigned to receive systemic glucocorticosteroid therapy. Five (3.18%) patients required complete discontinuation of immunotherapy due to immune-related toxicity. Conclusions . In real-world clinical practice, the combination of atezolizumab and chemotherapy demonstrated an acceptable and manageable toxicity profile, even when used in patients with a baseline reduced performance status and aggravated medical history.